Janssen to discontinue pimodivir influenza development program

Janssen to discontinue pimodivir influenza development program.janssen pharmaceutical -decision based on recent results from pre-planned interim analyses of pimodivir phase 3 trial in hospitalized patients with influenza a.janssen - data show that pimodivir does not offer a benefit above existing standard of care.janssen - pimodivir phase 3 trial in influenza a found pimodivir in combination with soc was very unlikely to demonstrate added benefit.janssen - study in hospitalized patients with influenza a and parallel phase 3 study of pimodivir in outpatients with influenza a will be halted.
VRTX Ratings Summary
VRTX Quant Ranking